InvestorsHub Logo
Followers 29
Posts 2181
Boards Moderated 0
Alias Born 03/21/2014

Re: None

Wednesday, 12/20/2023 5:25:53 PM

Wednesday, December 20, 2023 5:25:53 PM

Post# of 366
"In connection with the approval of LYFGENIA, we did not receive a Rare Pediatric Disease Priority Review Voucher that we requested as part of the FDA’s review. We are evaluating the FDA’s denial and plan to dispute this decision with the FDA."

https://ih.advfn.com/stock-market/NASDAQ/bluebird-bio-BLUE/stock-news/92864211/form-424b5-prospectus-rule-424b5
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLUE News